201 HASKINS WAY, SOUTH SAN FRANCISCO, CA
Cero Therapeutics Enters SPA Amendment to Increase Initial Closing by $500,000
Cero Therapeutics Enters $7 Million Securities Purchase Agreement
Investor Presentation
Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
News
News, Material Contracts
Other Events
Q2
Notice of Late Filing for Quarterly Report
Q1
Amended Annual Report
FY 2024
Notice of Late Filing for Annual Report
Amended Quarterly Report
Q3
Prospectus filed pursuant to Rule 424(b)(3)
PRER14A
PRE 14A
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
Definitive Revised Proxy Statement
Correspondence